Kenneth Webster
About Kenneth Webster
Kenneth Webster is a Senior Pharmacokineticist at Celerion in Edinburgh, United Kingdom, with over 20 years of experience in pharmacokinetics and regulatory affairs. He has held various positions in notable companies and has expertise in using Phoenix software for pharmacokinetic analyses.
Work at Celerion
Kenneth Webster has been employed at Celerion as a Senior Pharmacokineticist since 2017. He is based in Edinburgh, United Kingdom, and has contributed to various pharmacokinetic studies during his tenure. His role involves leading the pharmacokinetic phase of nonclinical and clinical studies, ensuring the accuracy and reliability of data related to drug absorption, distribution, metabolism, and excretion.
Previous Employment History
Before joining Celerion, Kenneth Webster held several positions in the pharmacokinetics field. He worked at Charles River Laboratories as Principal Pharmacokineticist from 2011 to 2017. Prior to that, he served as a Senior Pharmacokineticist at AAIPharma Services Corp. from 2007 to 2009. His career also includes roles at Quintiles and MDS Pharma Services, where he gained extensive experience in pharmacokinetics.
Education and Expertise
Kenneth Webster earned a Bachelor of Science degree in Biomedical Science from The University of Glasgow, completing his studies from 1996 to 2001. He possesses extensive expertise in using Phoenix (WinNonlin) software for pharmacokinetic analyses, including non-compartmental and compartmental methods. His skills also encompass PK/PD modeling and statistical evaluation, making him proficient in various aspects of pharmacokinetics.
Regulatory Affairs Experience
Kenneth Webster has regulatory affairs experience, having worked as a Regulatory Affairs Officer at Alba Bioscience from 2010 to 2011. In this role, he was responsible for ensuring compliance with licensing and marketing regulations for in vitro diagnostic medical devices. He liaised with regulatory bodies such as the FDA, ANVISA, and MHRA to facilitate appropriate legal compliance.
Leadership in Pharmacokinetic Studies
In his current role at Celerion, Kenneth Webster acts as the lead on the pharmacokinetic phase of various studies. His responsibilities include overseeing toxicokinetic, single/multiple ascending dose, radiolabelled, bioavailability/bioequivalence (BA/BE), and pharmacokinetic/pharmacodynamic (PK/PD) studies. His leadership ensures that studies are conducted effectively and meet regulatory standards.